Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01371825
Recruitment Status : Completed
First Posted : June 13, 2011
Results First Posted : April 18, 2016
Last Update Posted : January 30, 2019
Sponsor:
Information provided by (Responsible Party):
Alexion Pharmaceuticals

Brief Summary:
This was an open-label, repeat-dose, intra-participant dose-escalation study of SBC-102 (sebelipase alfa) in children with growth failure due to lysosomal acid lipase (LAL) Deficiency. Eligible participants received once-weekly (qw) infusions of sebelipase alfa for up to 5 years.

Condition or disease Intervention/treatment Phase
Lysosomal Acid Lipase Deficiency Wolman Disease Drug: Sebelipase alfa (SBC-102) Phase 2 Phase 3

Detailed Description:

LAL Deficiency is a rare autosomal-recessive lipid storage disorder that is caused by a marked decrease or almost complete absence of LAL, leading to the accumulation of lipids, predominately cholesteryl esters and triglycerides, in various tissues and cell types. In the liver, accumulation of lipids leads to hepatomegaly, liver dysfunction, and hepatic failure. Although a single disease, LAL Deficiency presents as a clinical continuum with 2 major phenotypes, Cholesteryl Ester Storage Disease (CESD) and Wolman Disease.

Early-onset LAL Deficiency (Wolman Disease) is extremely rare, with an estimated incidence of less than 2 lives per million. It is characterized by profound malabsorption, growth failure, and hepatic failure, and is usually fatal in the first year of life.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 9 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label, Multicenter, Dose Escalation Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of SBC-102 (Sebelipase Alfa) in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency
Actual Study Start Date : May 4, 2011
Actual Primary Completion Date : January 3, 2018
Actual Study Completion Date : January 3, 2018


Arm Intervention/treatment
Experimental: Open-Label Sebelipase Alfa
Participants received intravenous (IV) infusions of sebelipase alfa during the open-label treatment. Participants initially received 0.35 milligrams (mg)/kilogram (kg) qw and escalated to 1 mg/kg qw after demonstrating acceptable safety and tolerability during at least 2 infusions. One participant initiated treatment under a Temporary Use Authorization prior to enrollment, wherein the participant's dose was gradually escalated from 0.2 to 1 mg/kg over 4 weeks; the participant started the study at this dose. Participants on treatment for 96 weeks and on stable qw dosing for 24 weeks could be switched to an every other week (qow) dosing schedule. In the event of protocol-defined disease progression at any time during treatment, a participant could receive a dose increase from 1 to 3 mg/kg qw and, if necessary, a dose increase to 5 mg/kg qw with Safety Committee approval. Participants dosed qow who met dose-escalation criteria were reverted to qw dosing or escalated to 1 or 3 mg/kg qow.
Drug: Sebelipase alfa (SBC-102)
Sebelipase alfa is a recombinant human lysosomal acid lipase enzyme. The investigational medicinal product is an enzyme replacement therapy intended for treatment of participants with LAL Deficiency. Dosing occurred qw for up to 5 years.




Primary Outcome Measures :
  1. Percentage Of Participants In The Primary Efficacy Analysis Set (PES) Surviving To 12 Months Of Age [ Time Frame: Month 12 ]
    The primary efficacy endpoint was the percentage of participants (%) in the PES who survived to at least 12 months of age.


Secondary Outcome Measures :
  1. Percentage Of Participants Surviving Beyond 12 Months Of Age [ Time Frame: Baseline to Month 18, Month 24, Month 36, Month 48, and Month 60 ]
    The percentage of participants in the PES who survived to at least 18 months of age.

  2. Median Age At Death [ Time Frame: Baseline to Week 260 ]
    Participants in the PES who died during the study, including 3 participants who died after having received between 1 and 4 infusions of sebelipase alfa and 1 participant who died after approximately 40 weeks on treatment.

  3. Change From Baseline To Months 12, 24, 36, 48, And 60 In Weight For Age (WFA) Percentiles [ Time Frame: Baseline, Month 12, Month 24, Month 36, Month 48, and Month 60 ]
    Baseline is defined as the last measurement prior to the first infusion of sebelipase alfa.

  4. Number Of Participants With Stunting, Wasting, Or Underweight [ Time Frame: Baseline to Month 12, Month 24, Month 36, Month 48, and Month 60 ]

    The number of participants who met criteria for the following dichotomous indicators of under nutrition were reported. These indicators included the following:

    • Stunting was defined as at least 2 standard deviations below the median for length-for-age/height-for-age;
    • Wasting was defined as wasting at least 2 standard deviations below the median for weight-for-length/weight-for-height; and
    • Underweight was defined as at least 2 standard deviations below the median for WFA.

  5. Change From Baseline To Months 12, 24, 36, 48, And 60 In Serum Transaminases (ALT And AST) [ Time Frame: Baseline, Month 12, Month 24, Month 36, Month 48, and Month 60 ]
    Change from Baseline to Months 12, 24, 36, 48, and 60 for alanine aminotransferase (ALT) and aspartate aminotransferase (AST).

  6. Change From Baseline To Months 12, 24, 36, 48, And 60 In Serum Ferritin [ Time Frame: Baseline, Month 12, Month 24, Month 36, Month 48, and Month 60 ]
    The median change in serum ferritin from Baseline to Months 12, 24, 36, 48, and 60 is presented.

  7. Number Of Participants Achieving And Maintaining Transfusion-free Hemoglobin Normalization [TFHN] [ Time Frame: Baseline to Month 60 ]

    The number of participants achieving and maintaining TFHN are presented.

    For TFHN to be achieved, the participant must a) have had 2 post-baseline measurements of hemoglobin at least 4 weeks apart that were both above the age-adjusted lower limit of normal; b) have had no known additional measurements of hemoglobin that were below the age-adjusted lower limit of normal during the (minimum) 4-week period; and c) have had no transfusions during the (minimum) 4-week period, and also no transfusions for 2 weeks prior to the first hemoglobin measurement in the (minimum) 4-week period.

    For TFHN to be maintained, the participant must have been transfusion-free beginning at Week 6 and had all hemoglobin assessments above the lower limit of normal beginning in Week 8 and lasting at least 13 weeks.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 24 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participant's parent or legal guardian provided written informed consent/permission prior to any study procedures.
  • Male or female child with documented decreased LAL activity relative to the normal range of the laboratory performing the assay or documented result of molecular genetic testing (2 mutations) confirming a diagnosis.
  • Growth failure with onset before 6 months of age.

Exclusion Criteria:

  • Clinically important concurrent disease or comorbidities.
  • Had received an investigational product other than sebelipase alfa within 14 days prior to the first dose.
  • Participant was older than 24 months of age.
  • Myeloablative preparation, or other systemic pre-transplant conditioning, for hematopoietic stem cell or liver transplant.
  • Previous hematopoietic stem cell or liver transplant.
  • Known hypersensitivity to eggs.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01371825


Locations
Layout table for location information
United States, California
Irvine, California, United States, 92697
Egypt
Cairo, Egypt, 11771
France
Grenoble, France, 38700
Paris, France, 75015
Ireland
Dublin, Ireland, 1
United Kingdom
London, United Kingdom, SE1 7EH
Manchester, United Kingdom, M13 9WL
Sponsors and Collaborators
Alexion Pharmaceuticals
  Study Documents (Full-Text)

Documents provided by Alexion Pharmaceuticals:
Study Protocol  [PDF] January 5, 2016
Statistical Analysis Plan  [PDF] March 7, 2014


Publications:
Layout table for additonal information
Responsible Party: Alexion Pharmaceuticals
ClinicalTrials.gov Identifier: NCT01371825     History of Changes
Other Study ID Numbers: LAL-CL03
First Posted: June 13, 2011    Key Record Dates
Results First Posted: April 18, 2016
Last Update Posted: January 30, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Keywords provided by Alexion Pharmaceuticals:
Niemann-Pick Disease (NPD) Type C
LIPA
Wolman Disease
Wolman Phenotype
Acid Lipase Deficiency
Acid Cholesteryl Hydrolase
Acid Lipase Disease Deficiency, type 2
Cholesteryl Ester Storage Disease (CESD)
Cholesteryl Ester Hydrolase Deficiency
Early Onset Lysosomal Acid Lipase Deficiency (Wolman Disease)
LAL Deficiency
Late Onset Lysosomal Acid Lipase Deficiency (CESD)
Wolman Disease (early onset LAL Deficiency)
Related Disorders:
Non-alcoholic Fatty Liver Disease (NAFLD)
Non-alcoholic Steatohepatitis (NASH)
Alcoholic Liver Disease
Cryptogenic Cirrhosis
Chanarin Dorfman Syndrome

Additional relevant MeSH terms:
Layout table for MeSH terms
Lipid Metabolism, Inborn Errors
Metabolism, Inborn Errors
Failure to Thrive
Wolman Disease
Signs and Symptoms
Cholesterol Ester Storage Disease
Lipidoses
Genetic Diseases, Inborn
Lysosomal Storage Diseases
Infant, Newborn, Diseases
Lipid Metabolism Disorders
Metabolic Diseases